Opportunities and Risks of UK Medical Device Reform

Abstract

Objectives To identify the potential opportunities and risks around future UK regulatory reform of medical devices. Design A mixed methods approach, comprising a rapid literature review, one-to-one, semi-structured interviews with key stakeholders, a multidisciplinary stakeholder workshop, and a post-workshop survey. Setting United Kingdom. Participants 32 key stakeholders across the medical device sector were identified both from the public and private sectors. Results Opportunities relating to regulatory independence were identified, including the potential to create and implement a regulatory framework that ensures availability of medical devices; innovation and investment potential; and safety to the citizens of the UK. The most significant risks identified included threats to the safety of individual patients and the wider health system arising from the delay in awaiting regulatory approval due to the shortage of approved bodies; and reduced competitiveness of UK market and device manufacturers. Recommendations were identified to mitigate risks, centred on harnessing broader cross-sector collaborations, promoting patient and public partnership, and maximizing international engagement. Conclusions The UK’s medical device sector is at a time-critical juncture to construct a regulatory framework to navigate its exit of Europe and respond to Europe's transition to new medical device regulations whilst also addressing the ongoing demand for rapid approval for new devices in response to the global pandemic. Investment, capacity-building, and international engagement will play a central role in mitigating risks and maximizing opportunities for medical device regulation.

AI-Enabled Clinical Decision Support Tools for Mental Healthcare: A Product Review

“…The FDA's regulatory pathways include a) premarket approval (usually for Class III devices), which entails an exhaustive review that requires scientific evidence of safety and 3 Please note EUDAMED is still in transition so its usage isn't compulsory (European Commission, 2023a) efficacy, b) the 510(k) pathway (usually for Class II devices), which entails the evaluation of the safety and efficacy of a device based on a similar, previously approved (i.e., predicate) device, and c) the less rigorous De Novo premarket review that includes checks for safety and effectiveness for new technologies without a predicate device (FDA, 2023b(FDA, , 2023c. Similar regulatory processes apply for UKCA marking (see Han et al, 2022)…”

Prevention and management of health products shortages by the French national agency (ANSM), 10 years of experience

“…Regulatory authorities may also allocate huge amounts of resources to manage health products shortages. Therefore, the prevention of shortages has become a priority for authorities worldwide (11)(12)(13)(14)(15)(16)(17)(18)(19). This global problem requires the implementation of specific measures to improve prevention, anticipation, and ensure better coverage of medical needs.…”